Our Discovery Biology Unit provides validated discovery assays and biology services, including in vitro assays (HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling) and in vivo disease models such as tumor models, fibrosis disease models, kidney disease models, CNS models, pain models, inflammation models, liver disease models for cardiovascular, CNS, respiratory, metabolic and infectious diseases. Founded in 2008, we have multiple function teams of ~500 scientists, including 11% PhD, 55% MSc, and led by 12 seasoned scientific leaders with an average of 15 years of R&D experience in the US, Canada, and UK.
Capabilities at a Glance
- >400 global collaborators including 14 partners from the top 20 pharmaceutical companies
- 4 locations, including 400 scientists working on in vitro and in vivo biology in Shanghai, 30 scientists in our pharmacology team in Suzhou, and 50 scientists in Qidong.
- CAP-certified FACS, as well as pathology services and a molecular testing Laboratory for clinical virology
- A total of ~400 biologists, offering plate-based screening, and pharmacology services under FTE or FFS models
- >30 Ph.Ds trained in US & Canada, 10 with >15 years R&D experience
- 43,000 sq Ft of Biology labs and AAALAC-accredited animal facility
- 50,000+ sq Ft of new small animal facility is under construction at Qidong, Jiangsu
in vitro Biology
WuXi Biology offers comprehensive assays services that cover all major therapeutic target classes to support the in vitro pharmacological characterization. Our in vitro biology services include HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling.
in vivo Pharmacology
WuXi Biology has established multiple in vivo animal models to evaluate preclinical drug candidates. Each disease model is designed to understand specific aspects of drug property and its mechanism of action.
Oncology and Immuno-oncology Unit
Our innovative platform covers all research needs ranging from target discovery, in vitro and in vivo pharmacology, and translational research to clinical biomarker testing enabling drug discovery for cancer, autoimmune disease and rare genetic diseases (RGD).